Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on September 28, 2014. The filing discloses a material change in executive leadership and the entry into a definitive employment agreement.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Transition: The Board of Directors appointed Mr. Moshe Manor as the new President and Chief Executive Officer, effective November 2, 2014.
- Departure: Current CEO David Aviezer, Ph.D., will retire on November 2, 2014.
- Compensation Package: Mr. Manor's agreement includes a monthly base salary of approximately 100,000 New Israeli Shekels (approx. $27,120 USD) and an annual discretionary bonus based on Board-determined objectives.
- Equity Grant: Mr. Manor received options to purchase 900,000 shares of common stock at an exercise price of $2.37 per share. These options vest quarterly over four years (16 equal increments) with full acceleration upon a Corporate Transaction or Change in Control.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking financial guidance or specific risk factors beyond standard employment terms. The appointment highlights Mr. Manor's extensive background at Teva Pharmaceutical Industries Ltd., where he held senior roles including President of Teva Asia & Pacific and Group Vice President of Global Branded Products. The agreement is terminable by the Company with 90 days' notice during the first year and 180 days' notice thereafter, or immediately for cause.
Key Facts for Investor Verification
- Confirm the exact start date of Mr. Manor's tenure (November 2, 2014) and the retirement date of Dr. Aviezer.
- Verify the total potential equity value of the 900,000 options granted at $2.37 per share against current market prices.
- Review the specific performance metrics for the discretionary bonus, which are determined solely by the Board.
- Check for any additional press releases (Exhibit 99.1) regarding strategic shifts under the new leadership.